Screener
Gyre Therapeutics, Inc. GYRE Transaction Costs
Transaction Costs at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept gyre:TransactionCosts.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Gyre Pharmaceuticals | Gyre | Total |
|---|---|---|---|
| Research and development | 9,697 | 4,603 | 14,300 |
| Research and development - related parties | 4,836 | — | 4,836 |
| General and administrative | 4,268 | 3,594 | 7,862 |
| Transaction costs | — | 502 | 502 |
| Total segment operating expenses | 34,764 | 8,699 | 43,463 |
| Loss from segment operations | (5,667) | (8,691) | (14,358) |
| Other segment (loss) income, net: | |||
| Interest income | 252 | 488 | 740 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s transaction costs?
- Gyre Therapeutics, Inc. (GYRE) reported transaction costs of $502K in Q2 2026.
- What does transaction costs mean?
- Transaction Costs as reported by Gyre Therapeutics, Inc. Common Stock.
Ask your AI about Gyre Therapeutics, Inc.'s transaction costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude